Skip to content
In Stock Prasugrel
Blood Thinners

Prasugrel

People with acute coronary syndrome undergoing percutaneous coronary intervention may need Prasugrel to reduce platelet-driven clot formation. Prasugrel is an oral thienopyridine antiplatelet tablet…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Prasugrel
Select dosage:
Select pack Package Per unit Price
$ 9.55 $ 286.58
Free Regular Delivery $ 8.75 $ 573.16 $ 525.10 Save 8%
Free Express Delivery $ 8.41 $ 859.74 $ 756.50 Save 12%
Free Express Delivery $ 7.89 $ 1,146.32 $ 946.96 Save 17%
Free Express Delivery $ 7.64 $ 1,719.48 $ 1,375.94 Save 20%
Best value Free Express Delivery $ 6.79 $ 3,438.96 $ 2,443.94 Save 29%
$ 4.57 $ 137.06
$ 4.18 $ 274.12 $ 250.98 Save 8%
Free Regular Delivery $ 4.07 $ 411.18 $ 366.68 Save 11%
Best value Free Regular Delivery $ 3.77 $ 548.24 $ 452.12 Save 18%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

People with acute coronary syndrome undergoing percutaneous coronary intervention may need Prasugrel to reduce platelet-driven clot formation. Prasugrel is an oral thienopyridine antiplatelet tablet that blocks the platelet P2Y12 receptor. Its main benefit is stronger, more predictable platelet inhibition when prescribed with aspirin after coronary intervention.

Product information

Prasugrel belongs to the thienopyridine class of antiplatelet agents. It is a P2Y12 inhibitor, also described pharmacologically as a purinergic P2Y12 receptor antagonist and platelet aggregation inhibitor. The active medicine is prasugrel, commonly formulated as prasugrel hydrochloride.

Pharmacological Classification and International Branding

Prasugrel is a third-generation thienopyridine derivative. Unlike a direct-acting reversible inhibitor, it requires conversion in the body to an active metabolite before it produces its antiplatelet effect.

A useful distinction is that platelet inhibition is not the same as dissolving an existing clot. Prasugrel prevents and limits platelet-rich clot growth; it does not function as a thrombolytic medicine.

Ingredients

Prasugrel is the active medicine in this product and belongs to the thienopyridine class of antiplatelet agents. It is a P2Y12 receptor antagonist and platelet aggregation inhibitor. Prasugrel is commonly formulated as prasugrel hydrochloride and requires conversion in the body to an active metabolite before producing its antiplatelet effect.

Therapeutic indications

Prasugrel is prescribed in selected adults with acute coronary syndrome who are managed with percutaneous coronary intervention. Acute coronary syndrome includes unstable angina and myocardial infarction caused by reduced blood flow through a coronary artery.

Coronary artery disease can cause a ruptured plaque to expose substances that activate platelets. A coronary stent restores vessel diameter, yet the metal surface and the injured artery can promote platelet attachment during healing. Antiplatelet treatment reduces this risk.

The intended clinical benefit is a lower chance of ischaemic events, including myocardial infarction and stent thrombosis, when the medicine is appropriate for the patient. The Australian TGA and international cardiology guidance place strong emphasis on balancing this benefit against major bleeding risk [1].

Role in Percutaneous Coronary Intervention

Prasugrel is generally introduced as part of dual antiplatelet therapy, with aspirin providing a second platelet pathway of inhibition. The combination is used for a defined period chosen by the treating cardiology team.

Post-PCI monitoring involves more than checking whether chest pain has improved. Clinicians watch for bleeding from the access site, blood in urine or stool, unexplained bruising, falling haemoglobin, recurrent chest discomfort, and neurological symptoms.

Patients sometimes assume that a small bruise means treatment has failed. Small bruises can occur because platelet function is reduced, while sudden weakness, severe headache, black stools, or vomiting blood require urgent medical assessment.

Directions for use

Prasugrel is taken as tablets. The amount and frequency depend on the purpose of treatment and are agreed with a doctor or pharmacist. Cardiologists commonly use an initial loading dose during or around PCI, followed by a once-daily maintenance dose.

The treatment plan can include:

  • A loading dose selected for the acute coronary event and PCI setting.
  • A maintenance dose taken at the same time each day.
  • Aspirin as the second component of dual antiplatelet therapy.
  • A duration determined by stent-related risk, bleeding risk, and recovery.
  • Review of the plan before surgery, invasive procedures, or changes in anticoagulant treatment.

Prasugrel tablets may be taken with or without food unless the prescriber gives different instructions. Swallow the tablet with water. Do not double the next dose after a missed dose; the correct action depends on how close the next scheduled dose is and the individual treatment plan.

The FDA prescribing information describes prasugrel dosing within the acute coronary syndrome and PCI setting, with special restrictions for older adults and people with lower body weight [2].

A phone reminder linked to a regular daily activity can reduce missed maintenance doses. Keep the reminder separate from any instruction to take extra tablets after a missed dose.

When not to use it

The medicine is generally ruled out or requires specialist review in the following situations:

  • Previous transient ischaemic attack or stroke.
  • Active pathological bleeding.
  • Previous intracranial bleeding.
  • Severe liver disease or a condition that substantially raises bleeding risk.
  • Known allergy to prasugrel or another thienopyridine.
  • Age 75 years or older, unless a cardiologist identifies a strong clinical reason.
  • Body weight below 60 kg, where a lower maintenance approach may be considered.
  • Planned coronary artery bypass graft surgery.
  • Pregnancy or breastfeeding, unless the cardiology and obstetric teams judge treatment necessary.
  • Concurrent anticoagulant treatment or repeated use of non-steroidal anti-inflammatory medicines.

The combination with warfarin, direct oral anticoagulants, heparins, or fibrinolytic medicines can substantially increase bleeding. Selective serotonin reuptake inhibitors, corticosteroids, and regular ibuprofen can also add bleeding risk.

The EMA product information highlights the need to assess age, body weight, previous cerebrovascular disease, surgery, and concomitant medicines before prasugrel is selected [4].

When this is not for you

NOT for you if you have had a stroke or transient ischaemic attack, have active bleeding, or cannot follow the prescribed monitoring plan.

Unwanted effects

Bleeding is the main adverse effect associated with Prasugrel. It can appear as nosebleeds, gum bleeding, bruises, prolonged bleeding from small cuts, heavier menstrual bleeding, blood in urine, or black stools.

More serious bleeding can occur in the gastrointestinal tract, inside the skull, or at a surgical site. Emergency assessment is needed for vomiting blood, coughing blood, severe or persistent headache, sudden weakness, confusion, fainting, or a rapidly enlarging bruise.

Other possible problems include:

  • Anaemia caused by ongoing blood loss.
  • Low blood pressure after substantial bleeding.
  • Hypersensitivity reactions, such as rash, swelling, or breathing difficulty.
  • Rare thrombotic thrombocytopenic purpura, involving low platelets and small-vessel clotting.
  • Bleeding from the arterial access site after coronary intervention.

Prasugrel does not cause the typical stomach irritation associated with aspirin, yet the combination with aspirin can raise the total bleeding burden. Alcohol can also increase the chance of falls, stomach irritation, and poor judgement around bleeding symptoms.

One practical detail is easy to miss: shaving cuts, flossing injuries, and vigorous contact sports may produce longer bleeding during treatment. A bruise that expands without a clear injury deserves attention.

Mechanism of action

Mechanism of Action and Platelet Inhibition

Prasugrel is converted in the liver and other tissues into an active metabolite. This metabolite binds irreversibly to the platelet P2Y12 receptor, which normally responds to adenosine diphosphate, or ADP. This receptor helps amplify platelet activation. Blocking it reduces platelet aggregation. The effect supports prevention of new platelet-rich clots after PCI.

The sequence is straightforward:

  • Prasugrel enters the bloodstream after oral administration.
  • Enzymatic conversion produces the active metabolite.
  • The active metabolite attaches to the P2Y12 receptor.
  • ADP signalling is reduced.
  • Platelet activation and aggregation become less likely.

Because the interaction is irreversible, an affected platelet remains inhibited for its lifespan. New platelets must be produced before normal platelet activity returns. This explains why bleeding precautions continue after the last tablet.

Metabolic Conversion and Receptor Antagonism

Prasugrel generally produces more consistent platelet inhibition than clopidogrel because its activation pathway is less dependent on variable metabolic steps. The clinical effect still varies between patients, and a stronger antiplatelet effect also means a greater need to screen for bleeding hazards.

High on-treatment platelet reactivity describes platelet activity that remains higher than intended during treatment. It may contribute to thrombotic events, while excessive inhibition increases bleeding risk. These are opposite clinical problems, so dose selection cannot be based on potency alone.

Common mistakes

Several practical errors can reduce the benefit of treatment or increase harm:

  • Stopping Prasugrel because bruising has appeared without contacting the treatment team.
  • Taking an extra tablet after a missed dose.
  • Adding ibuprofen or naproxen for pain without checking the bleeding risk.
  • Forgetting to mention Prasugrel before dental extraction or surgery.
  • Taking aspirin irregularly when it forms part of the prescribed dual regimen.
  • Assuming a tablet can replace urgent assessment for new chest pain.
  • Underestimating black stools, persistent nosebleeds, or blood in urine.
  • Sharing tablets with a relative who has coronary disease but a different bleeding profile.

One less obvious mistake involves over-the-counter cold remedies. Some products contain anti-inflammatory ingredients that can increase bleeding, even when the patient does not consider them to be pain medicines.

Comparison

Prasugrel, clopidogrel, and ticagrelor all target P2Y12-related platelet activation, yet they differ in activation, reversibility, and bleeding profile.

Medicine or category Pharmacological profile Main clinical trade-off
Prasugrel Irreversible thienopyridine P2Y12 inhibition after activation Strong, predictable inhibition with significant bleeding restrictions
Clopidogrel Irreversible thienopyridine requiring several metabolic steps Variable response and possible drug resistance
Ticagrelor Reversible, direct-acting P2Y12 inhibition Rapid effect, with bleeding and breathlessness concerns

Clopidogrel remains useful in many cardiovascular situations, yet genetic differences, drug interactions, and metabolic variability can produce reduced platelet inhibition. The term drug resistance is often used when platelet activity remains high despite treatment.

Ticagrelor does not require the same type of metabolic activation as Prasugrel and has a reversible binding pattern. Its clinical profile differs, so the choice depends on the coronary event, bleeding risk, respiratory symptoms, heart rhythm, kidney function, and planned procedures.

Prasugrel may be favoured when a strong and predictable antiplatelet effect is needed during PCI. It is unsuitable for some patients, including those with a previous transient ischaemic attack or stroke. The TRITON-TIMI 38 trial found reduced ischaemic events with prasugrel in selected PCI patients but also identified clinically meaningful bleeding concerns [3].

What doctors say

In cardiology practice, Prasugrel is viewed as a specialised PCI medicine rather than a general treatment for chest discomfort. It is selected when the expected reduction in platelet-mediated coronary events outweighs the risk of bleeding.

Doctors usually focus on four questions:

  • Was the coronary event treated with PCI?
  • Has the patient had a previous stroke or transient ischaemic attack?
  • Is body weight below 60 kg or age advanced?
  • Are anticoagulants, surgery, kidney disease, liver disease, or recurrent bleeding present?

The most common prescribing mistake is treating the tablet as if it were a short course that can be stopped whenever the patient feels better. The stent remains part of the patient’s coronary anatomy after symptoms improve, and premature interruption can expose the patient to thrombosis.

A cardiologist may later adjust dual antiplatelet therapy, but that decision follows the balance between ischaemic risk and bleeding risk. The American College of Cardiology and American Heart Association describe antiplatelet duration as an individualised decision rather than one fixed schedule for every PCI patient [5].

What customers often ask

Can alcohol be used while taking Prasugrel?

Alcohol is not a simple food interaction with Prasugrel, but it can increase practical bleeding hazards through falls, stomach irritation, and impaired judgement. The NHS antiplatelet safety information reviewed in 2024 advises caution because heavy alcohol use can contribute to gastrointestinal bleeding and missed doses. A person with previous stomach bleeding, liver disease, or frequent alcohol intake needs a specific risk assessment before drinking.

What should happen if the expected cardiovascular result does not occur?

New chest pain, breathlessness, fainting, sweating, or pain spreading to the arm or jaw requires emergency assessment rather than an extra Prasugrel tablet. The TGA product information for prasugrel, reviewed in 2025, advises urgent assessment for recurrent acute coronary symptoms, even when antiplatelet treatment is being taken. Prasugrel reduces platelet-related risk but cannot reopen a completely blocked artery or treat every cause of chest pain.

What happens after stopping Prasugrel, and does it need tapering?

Prasugrel is not usually tapered because its antiplatelet effect gradually decreases as new platelets enter the circulation. The British National Formulary guidance reviewed in 2025 still supports planned interruption rather than abrupt unsupervised cessation. Stopping too early after PCI can raise the risk of stent thrombosis, so the timing must be agreed with the cardiology team.

Can people under 18 use Prasugrel?

Routine use under 18 requires a specialist decision because paediatric evidence is limited and bleeding consequences can be serious. The EMA product information for prasugrel, reviewed in 2024, does not support treating children as small adults with the same coronary protocol. A paediatric cardiologist would need to define the indication, dose, monitoring, and duration.

Does Prasugrel cause shortness of breath?

Shortness of breath is not the characteristic adverse effect associated with Prasugrel, though bleeding-related anaemia or a new cardiac event can cause breathlessness. The FDA Effient prescribing information, reviewed in 2025, advises urgent assessment when breathlessness occurs with chest pain, fainting, weakness, or signs of bleeding. Do not assume that breathlessness is a harmless tablet effect.

How long does one dose of Prasugrel keep working?

A dose begins platelet inhibition after conversion to its active metabolite, while the affected P2Y12 receptors remain blocked for the life of the platelet. The EMA Summary of Product Characteristics for prasugrel, reviewed in 2024, explains why platelet function does not return immediately after one dose is stopped. Recovery is gradual as new platelets are produced, which is why planned surgery may require several days of preparation.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Sources

  1. Therapeutic Goods Administration (TGA) (2024). Product Information — Efient (prasugrel hydrochloride).
  2. U.S. Food and Drug Administration (FDA) (2025). Effient (prasugrel) prescribing information.
  3. Wiviott SD, et al. (2007). Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes.
  4. European Medicines Agency (EMA) (2023). Summary of Product Characteristics (SmPC) — prasugrel.
  5. American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (2021). 2021 Guideline for Coronary Artery Revascularization.

How Buyers Rate Prasugrel

Based on 4 reviews

Steven B., 35 Verified
Rating: 5 out of 5

I took Prasugrel after a stent procedure and used a phone reminder for the daily tablet. Bruises on my forearms were more noticeable during the first month, but I did not have nosebleeds or stomach symptoms.

1 month 11 Nov 2026
Richard, 61 Verified
Rating: 3.5 out of 5

The tablets were part of my treatment after an acute coronary event. I stopped for several days because I was worried about bleeding gums, then contacted the cardiology clinic and restarted the planned schedule. I wish I had asked before stopping.

Several weeks 15 Nov 2026
Christopher, 35 Verified
Rating: 4 out of 5

I used Prasugrel with aspirin after PCI. The medicine itself was easy to take, although a small cut from gardening took longer to stop bleeding. My dental appointment was rearranged after I mentioned the antiplatelet treatment.

2 months 19 Oct 2026
Daniel P., 51 Verified
Rating: 5 out of 5

I had no major problems during the first weeks, but I felt uneasy about bruising and avoided ibuprofen. The cardiology team explained which pain medicines were unsuitable and gave me a clear plan for the next procedure.

Several weeks 26 Oct 2026
Get our free app Shop faster and track your orders 3.8 · 494 reviews Install